Akari Therapeutics (AKTX) Long-Term Deferred Tax (2022 - 2023)
Akari Therapeutics recorded quarterly Long-Term Deferred Tax of $42.2 million in Q4 2023, up 22.03% quarter-over-quarter from $34.6 million in Q4 2022, and up 22.03% year-over-year from $34.6 million in Q4 2022.
Akari Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $42.2 million for Q4 2023.
- In Q4 2023, Long-Term Deferred Tax rose 22.03% year-over-year to $42.2 million; the TTM figure through Dec 2023 stood at $42.2 million (up 22.03% YoY), while the FY2023 annual figure was $42.2 million, up 22.03% from the prior year.
- Long-Term Deferred Tax came in at $42.2 million for Q4 2023 at Akari Therapeutics, up from $34.6 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $42.2 million in Q4 2023 to a low of $34.6 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 42.24 Mn |
| Dec 31, 2022 | 34.62 Mn |